Member Info for avctIPmatters

"and we are thrilled to partner with Avacta in support of their efforts to bring game-changing new therapies to patients in need.”

Very impressive -

"Hear the story of Tempus and how the company is advancing precision medicine through the practical application of artificial intelligence in healthcare. Learn how the Tempus Platform was built to amass one of the largest libraries of clinical and molecular oncology data in the world, which allows physicians to make data-driven decisions in near real time to deliver personalized care and researchers to optimize discovery and development of therapeutics."

https://www.youtube.com/watch?v=XLO8kPcMXJk

FYI https://www.youtube.com/watch?v=XLO8kPcMXJk

O.K.N.V.I. RESIST-5 How to use product presentation

https://www.youtube.com/watch?v=Ylw2GcQCiks&feature=youtu.be

----------

Doing my bit to share

------------------

Exciting News from Coris BioConcept! 🚀

We are super proud to announce that our latest video is now available on our Youtube channel!

It will walk you through the step-by-step process of using our O.K.N.V.I. RESIST-5 (detection of OXA-48, KPC, NDM, VIM and IMP carbapenemases), demonstrating how simple and efficient it is to achieve reliable results. 🎯

Whether you’re already familiar with our products or just getting started, this is a valuable resource to see our test in action. Take a look and stay updated on the best practices for accurate diagnostics! 🧫

🔗 https://lnkd.in/gsUV3SHV

Don't hesitate to like & share!

hashtag#Diagnostics hashtag#RapidTesting hashtag#Healthcare hashtag#Innovation hashtag#HowToUse hashtag#CorisBioConcept hashtag#AMR hashtag#Biotech hashtag#MedicalDevices

Sounds good no disagreement from me ; However would like to see greater institutional/strategic biotech investers taking an investment interest "

"There are currently no individually significant shareholders holding in excess of 3%.

As at 2nd September 2024, the company has 362,159,730 ordinary shares of 10p each in issue."

So might need to wait a bit longer before moving to a bigger exchange . Perhaps dependent on positive additional patient trial data new few months.

Meantime the joy of being on AIM market message boards restricted to just a few probably wider audience blissfully unaware - Need to get them on the Avacta Science radar .

Whether by accident or design Avacta seem to have cracked it . Look forward not back .

--Disclosure - £63k invested - Zero profit - yes not great capital management -42.42%. defcit.

The best is still to come .

Good luck everyone ,

Thanks for sharing -

Note we should get follow up on how the visit went :

https://x.com/OndoPlc/status/1845817416627925324

"Ondo InsurTech Plc

@OndoPlc

CEO Craig Foster is en route to the ITC conference in Las Vegas, noting the significant growth of LeakBot in 🇺🇸- launching 4 States and 5 partnerships in 12 months

#ONDO has meetings this week with range of leading US insurers and U.S. investment banks too with updates to follow"

About Avacta - Nice summary some new info added in layman terms -

https://avacta.com/about/

Rorydinho Good info thanks for sharing nice to read : Might be some hidden value in those Avacta IP assets me thinks --exciting times to be a shareholder .

Note photo updated today wonder if might be the new CFO appointment ?

----------

Paul Fry

Non Executive Director

Paul was appointed as a Non- executive Director in February 2020. Paul has extensive financial experience across several industries including biotech, pharmaceutical and telecommunications. Paul was recently Chief Financial Officer of Argenta, a global CRO and CDMO specialising in animal health. Prior to this he was Chief Financial Officer of Vectura Group Ltd, an industry-leading inhaled drug delivery specialist which up until 2021 was listed on the FTSE Main Market.

Paul was also Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor technology. Paul has also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GlaxoSmithKline (‘GSK’), where he held several senior roles including Head of Global Finance Services and Chief Financial Officer for GSK’s Italian pharmaceutical business.

Paul holds a degree from Oxford University and is a member of the Chartered Institute of Management Accounts

Paul is Chair of the Audit Committee and a member of the Remuneration Committee.

Click /open : AVA 6000 6103 7100 (7103) buttons -gives moe details

https://avacta.com/pipeline/

URL Images Last Mod.

https://avacta.com/stage-products/ava6000/ 0 2024-10-16 08:46 +00:00

https://avacta.com/stage-products/ava7100/ 0 2024-10-16 09:00 +00:00

https://avacta.com/stage-products/ava6103/ 0 2024-10-16 09:16 +00:00

Good Morning

New website page coming soon - not yet activated .

URL Images Last Mod.

https://avacta.com/stage-products/ava7100/

https://avacta.com/stage-products-sitemap.xml 2024-10-16 07:21 +00:00

Also this one to check dates

https://avacta.com/sitemap_index.xml

Find this link useful you can see audit trail of pages etc

https://web.archive.org/web/20241001113538/https://avacta.com/

Agree .

Not had a proper look look yet might just be removing Wetherby details -

https://avacta.com/precision/ 0 2024-10-15 15:47 +00:00

https://avacta.com/precision/precision-drug-conjugate-pdc/ 0 2024-10-15 15:48 +00:00

https://avacta.com/precision-immuno-peptide-drug-conjugate/ 0 2024-10-15 15:50 +00:00

https://avacta.com/precision-adc/ 0 2024-10-15 15:51 +00:00

Website updated today - sorry can't remember the previous wording this might be identical :

https://avacta.com/precision/partnering/ 2024-10-15 09:54 +00:00

"Partnering for success

Partnering is key to Avacta’s strategy as we continue to expand our pipeline of innovative treatments for cancer.

Our partnering strategy includes teaming up with pharmaceutical partners to help advance our pipeline products through to market, as well as combining our proprietary platforms with novel warheads to develop next generation cancer therapies.

Contact us

To explore how we can work together, please contact our Chief Business Officer.

simon.bennett@avacta.com

Avacta Group plc

---

perhaps just tidying up page removing Wetherby details

Guess new CSO will concentrate on getting the Next GEN pipeline warheads ready for transfer to partners for them to take through the later stage clinical trials process . Roll out the pre|CISIONTM platform conveyor belt warheads delivery system with different cancer drugs to treat all kinds of cancer .

AVA6000 will set the scene then wagons roll .

Michelle Morrow, Ex F-star, Eliot Forster still pulling the strings jobs for the girls e.g Darlene Deptula-Hicks

Perhaps not quite yet - translation ?